Background: Pooled analysis of the TORO comparative clinical trial data sets showed a significantly higher incidence rate (IR) of bacterial pneumonia (BP) among patients treated with enfuvirtide-containing combination antiretroviral therapy (ENF-cART) than in those treated with other cART regimens. . The ENF-cART and cART groups consisted of 1220 and 9374 patients, respectively. Poisson regression models were used to quantify the relationship between ENF-cART therapy and the risk of BP.
Introduction
Highly effective combination antiretroviral therapy (cART) has transformed the outlook of HIV-infected patients. 1, 2 However, viral suppression is sometimes incomplete, necessitating a switch to more effective antiretroviral combinations. 3 As the number of HIV-1-infected patients exposed to several antiretroviral combinations has grown, the management of multidrug resistance and long-term toxicity has become a major challenge. 4 -7 Enfuvirtide (or T-20) is the first of a novel class of antiretrovirals known as HIV fusion inhibitors. 8,9 -14 Its efficacy and safety, when combined with an optimized background antiretroviral regimen, were mainly shown in two international randomized trials named TORO1 15 and TORO2. 13, 15, 16 However, a safety analysis of pooled data showed a significantly higher incidence of pneumonia in the enfuvirtide group than in the control group both at week 24 [4.9 versus 0.6 cases per 100 person-years (PYs), P ¼ 0.02] and at week 48 (6.7 versus 0.6 per 100 PYs). 15, 17 The aim of this study was to examine the possible influence of enfuvirtide-containing cART (ENF-cART) on the risk of bacterial pneumonia (BP) in patients included in the French Hospital Database on HIV (FHDH-ANRS CO4).
Materials and methods

Study population
The database
The FHDH clinical epidemiological network is a large prospective cohort involving 62 French hospitals belonging to 29 HIV/AIDS treatment and information centres (CISIH). 18, 19 FHDH inclusion criteria are HIV-1 or HIV-2 infection, and signed written informed consent. Trained research assistants prospectively collect clinical, biological and therapeutic data from medical records by using specialized software (DMI2, property of the French Ministry of Health). A follow-up form is completed at each visit or hospital admission for an HIV-related clinical event or a new treatment prescription, or at least every 6 months. The FHDH was approved by the French data protection authority (Commission Nationale de l'Informatique et des Libertés, CNIL).
Patients
We selected HIV-1-infected patients from the FHDH 18, 19 who were aged at least 15 years and who were followed between 1 January 2001 (when enfuvirtide became available in France) and 31 December 2006 (last update of the FHDH). In this period, patients were eligible if they had taken cART for at least 6 months before enrolment in the study, if they were then switched to a new cART regimen while their CD4 count was ,350 cells/mm 3 and if they had at least two subsequent follow-up visits and no previous history of BP. CART was defined as a combination of three or more antiretroviral drugs, or two ritonavir-boosted protease inhibitors (PIs), or one ritonavir-boosted PI plus one non-nucleoside reverse transcriptase inhibitor (NNRTI). To study the impact of ENF-cART on the risk of BP, we divided the selected population into patients switching to a new cART regimen that included enfuvirtide (ENF-cART group) and patients switching to a new cART regimen without enfuvirtide (cART group).
Statistical analysis
Follow-up data
Baseline was defined as the date of the cART switch. Follow-up data were censored at the date of enfuvirtide interruption in the ENF-cART group and at the date of cART interruption or addition of enfuvirtide in the cART group, or at the date of death, or 31 December 2006. Moreover, beyond these specified conditions, patients could change their cART without being censored. The CD4 cell counts and plasma viral load (pVL) were analysed as time-updated values from baseline to the end of follow-up. We used linear interpolation to fill in missing CD4 counts and pVL values between two registered values. For patients whose follow-up was ongoing, the last recorded CD4 count and pVL values were carried forward by 2 months. Other missing values were categorized as missing data. Patients were still considered to be on ENF-cART or cART 15 days after the last registered follow-up visit.
Event definition
Diagnosis of BP was based on information provided by physicians in each hospital. All diagnoses of BP, both definite (new X-ray evidence not present earlier with bacteriological documentation) and presumptive (new symptoms, signs or X-ray evidence not present earlier and no diagnosis of Pneumocystis jirovecii pneumonia or Mycobacterium disease), were considered for the study. 20, 21 First BP, occurring at least 15 days after the baseline point, was considered for the analysis.
Statistical methods
The BP incidence rates (IRs) in each group were calculated by dividing the number of patients who had BP during the entire follow-up period by the number of PYs at risk in the same group, both overall and within different CD4 cell count strata and pVL strata. Poisson regression models were used to quantify the relationship between ENF-cART therapy and the incidence of BP. The following potential factors were considered: sex, age, the HIV transmission group, sub-Saharan origin, the time period, the CD4 cell count and pVL strata, AIDS status 19 and co-trimoxazole prophylaxis. For multivariate Poisson regression analysis we first used bivariate analyses to identify potential confounders that changed the enfuvirtide-related relative rate (RR) of BP by 10%, with adjustment for the relevant variables. Statistical analyses were performed with the SAS software package version 9.1 (SAS Institute).
Results
Patients' characteristics
During the period 2001-2006, 1220 and 9374 patients, respectively, were selected for the ENF-cART and cART groups. Follow-up totalled 1531 and 26 198 PYs, respectively. During this period, the yearly median number of medical appointments was similar in the two study groups, between 6 and 8 for the ENF-cART group and between 3 and 11 for the cART groups. The median durations between the first two visits were 28 days [interquartile range (IQR) 14 -53] and 56 days (IQR 28-99) in the ENF-cART and cART groups, respectively. The first two visits thus were within the first year of inclusion in the study.
In the ENF-cART group the baseline median CD4 count was 100 cells/mm 3 (IQR 31 -196), 55.2% of patients had already had an AIDS-defining event and 10.2% of patients had pVL values ,500 copies/mL ( Table 1 ). The median duration of prior cART was 86 (IQR 70-99) months, the median number of previously taken antiretroviral drugs was 12 (IQR 9-13) and 788 patients (64.6%) had previously received at least one NRTI, one PI and one NNRTI. Follow-up totalled 557 PYs in the ,100 CD4 cells/mm 3 stratum, 749 PYs in the 100-349 cells/mm 3 stratum, 206 PYs in the 350 cells/mm 3 stratum and 19 PYs in the missing values stratum. Follow-up totalled 578 PYs in the ,500 copies/mL stratum, 445 PYs in the 500-49 999 copies/mL stratum and 480 PYs in the 50 000 copies/mL stratum.
In the cART group, the baseline median CD4 count was 211 cells/mm 3 (IQR 128-282), 37.7% of the patients had already had AIDS-defining events and 38.5% of patients had pVL values ,500 copies/mL ( Table 1 ). The median duration of prior cART was 59 (IQR 41-72) months, the median number of previously taken antiretroviral drugs was 6 (IQR 4-8) and 2116 patients (22.6%) had previously received at least one NRTI, one PI and one NNRTI. Follow-up totalled 3531 PYs in the ,100 CD4 cells/mm 3 IQR, interquartile range; ENF, enfuvirtide; cART, combination antiretroviral treatment; ENF-cART, enfuvirtide-containing cART; BP, bacterial pneumonia; pVL, plasma viral load. Bacterial pneumonia and enfuvirtide-containing cART 141 JAC stratum, 6150 PYs in the 500-49999 copies/mL stratum and 3371 PYs in the 50000 copies/mL stratum. (Table 1) . Table 2 shows the RR of BP associated with enfuvirtide treatment alone and with enfuvirtide treatment associated with each studied covariate. In univariate analysis the RR for BP was twice as high among patients on ENF-cART as among patients on cART (RR 2.09; 95% CI 1.08-4.02). All the studied covariates were associated with the risk of BP in univariate analyses. After separate adjustment for each covariate, however, only the time period, the CD4 cell count and pVL modified the relationship between enfuvirtide exposure and BP by 10%. After adjustment, the RR of BP associated with enfuvirtide treatment was not statistically significant (RR 1.39; 95% CI 0.46 -4.13) ( Table 3) . Only a lower CD4 cell count and a higher pVL value were independently associated with an increased risk of BP. HIV infection is associated with a 5-to 25-fold increase in the risk of BP and invasive pneumococcal disease, despite a decrease in the incidence of invasive pneumococcal disease since the beginning of the cART era in 1996. 22 -24 Other reported risk factors are age, cigarette smoking, injection drug use, a low CD4 cell count and a high pVL value; in contrast, co-trimoxazole prophylaxis and cART are protective.
Comparative IRs of BP
-24
Although we found that adjusted BP risk ratio was not significantly increased by enfuvirtide treatment (RR 1.39; 95% CI 0.46 -4.13), the estimated risk was higher than 1.00 and we cannot exclude a small increased risk. In the TORO study, the crude relative risks of BP associated with enfuvirtide were 8.17 at week 24 and 11.17 at week 48. Our study including 1220 patients in the ENF-cART group and 9374 patients in the cART group, with 10 and 82 events, respectively, had a power of 90% to show an RR of BP of at least 2.5 and a power of 95% to show an RR of at least 4 between the ENF-cART group and cART group. 25 Nevertheless, despite having enough power, we did not show such risks. As the upper limit of the CI is 4.13, our results are compatible with a small increase of the real risk, but much smaller than previously seen in the TORO study.
Some relevant information is lacking in the FHDH. For example, pneumococcal vaccination status is not recorded, but the 23-valent polysaccharide vaccine has been recommended for HIV-infected patients with a CD4 count ,500 cells/mm 3 only since 2006 in France. 26 Smoking status is not recorded either, but smoking is not known to influence enfuvirtide prescription. The overall incidence of BP may be underestimated in the FHDH database, as some cases may have been managed solely on an outpatient basis. However, the frequency of such events is likely to have been the same in the two groups studied here, especially as the yearly number of medical appointments was the same during the study period. The large number of patients included in the FHDH allows us to investigate rare events. Different follow-up could explain a different crude percentage of BP events between TORO and our study but not different IRs for which estimation takes into account duration of follow-up on enfuvirtide. However, enfuvirtide was mostly prescribed late in the 2001-2006 period and patients frequently Kousignian et al.
switched their ENF-cART to a cART without enfuvirtide after immune recovery, both explaining the shorter follow-up duration in the ENF-cART group than in the cART group and than in the TORO study. As estimation of the IRs takes into account the different follow-up durations in the study groups, this should not have over-or underestimated the incidence of BP in our study. The incidence of pneumonia observed in the TORO studies was similar to that reported during the early cART era. 17 We excluded cases of pneumonia occurring during the first 15 days of the switch regimen, in order to avoid any influence of the previous antiretroviral regimen on the frequency of BP (even though the results were similar when these cases were included in the analysis; data not shown). In the TORO studies it may be noteworthy that 9 of the 45 cases of pneumonia observed among patients allocated to the enfuvirtide group occurred during the first month of treatment.
The incidence of BP in the ENF-cART group of our study was much lower than that observed in the enfuvirtide arms of the TORO studies, but it was very similar to that observed in the control group of the TORO studies. The patients included in the TORO studies had lower baseline CD4 cell counts, more frequent previous AIDS-defining events, higher baseline viral replication and a longer follow-up, and this may explain the different IRs observed between the enfuvirtide-treated patients in our study and in the TORO trials. 15, 17 Nevertheless, the BP IRs in our study were similar to those observed in other recent cohort studies involving patients with similar baseline immunovirological and treatment status. 22, 27 Studies performed early during the cART era (1996-2000) gave higher IRs, 23, 28 but the risk of BP has fallen in recent years, related to longer duration of efficient viral suppression on cART. 24 The arrival of less toxic antiretroviral drugs in recent years may have improved treatment adherence and, thus, patients' immune status.
The main finding of this study is that patients starting an ENF-cART regimen were more immunosuppressed than patients starting other cART regimens, with lower CD4 cell counts, more previous AIDS-defining events and higher viral replication. ENF-cART was associated with a higher frequency of BP in univariate analysis, but this difference disappeared in multivariate analysis with stratified CD4 cell counts and pVL values.
In conclusion, this study-the largest observational cohort study of this issue-showed no significant difference in the incidence of BP between patients receiving cART with and without enfuvirtide, after adjustment for potential confounding factors. As the upper limit of the CI is 4.13, our results are compatible with a small increase of the real risk, but much smaller than previously seen in the TORO study.
